Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nutratech prevails in patent case

This article was originally published in The Tan Sheet

Executive Summary

Under a settlement to its patent infringement lawsuit announced Oct. 19, Syntech International acknowledges the validity and infringement of U.S. patents licensed exclusively to West Caldwell, N.J.-based Nutratech on the use of Citrus aurantium (bitter orange) extract for stimulating thermogenesis, reducing weight and suppressing appetite, Nutratech says. Irvine, Calif.-based Syntech agreed to a permanent injunction, immediately ceasing the import and sale of Citrus aurantium extract and will pay damages to Nutratech based upon its past infringement, according to Nutratech. The firm's Advantra Z thermogenic ingredient contains its proprietary Citrus aurantium extract, covered by a patent it licenses from Zhishin Capital LLC...

You may also be interested in...

Job Cuts As Polyphor Focuses On First-In-Class Anticancer

Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.


Canada Introduces eCTD To Ease Clinical Trial Filings

Filing for clinical trial activities in the electronic common technical document format via the Common Electronic Submission Gateway is expected to help sponsors send their information in a secure manner, with reduced transmission times and cost.

Ireland Embarks On New Stage Of Drug Verification System

The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts